Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Intangibles (2016 - 2025)

Ani Pharmaceuticals' Change in Intangibles history spans 13 years, with the latest figure at $159000.0 for Q4 2025.

  • For Q4 2025, Change in Intangibles rose 84.88% year-over-year to $159000.0; the TTM value through Dec 2025 reached $20.5 million, up 2757.18%, while the annual FY2025 figure was $20.5 million, 2757.18% up from the prior year.
  • Change in Intangibles for Q4 2025 was $159000.0 at Ani Pharmaceuticals, up from $60000.0 in the prior quarter.
  • Across five years, Change in Intangibles topped out at $21.0 million in Q2 2021 and bottomed at $4000.0 in Q4 2022.
  • The 5-year median for Change in Intangibles is $229000.0 (2022), against an average of $3.5 million.
  • The largest annual shift saw Change in Intangibles tumbled 99.93% in 2021 before it surged 62400.0% in 2023.
  • A 5-year view of Change in Intangibles shows it stood at $12000.0 in 2021, then crashed by 66.67% to $4000.0 in 2022, then soared by 62400.0% to $2.5 million in 2023, then tumbled by 96.56% to $86000.0 in 2024, then soared by 84.88% to $159000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Change in Intangibles are $159000.0 (Q4 2025), $60000.0 (Q3 2025), and $2.9 million (Q2 2025).